Examining the Association of Billed Advance Care Planning With End-of-Life Hospital Admissions Among Advanced Cancer Patients in Hospice

Am J Hosp Palliat Care. 2022 May;39(5):504-510. doi: 10.1177/10499091211039449. Epub 2021 Aug 24.

Abstract

Background: Advance care planning (ACP), or the consideration and communication of care preferences for the end-of-life (EOL), is a critical process for improving quality of care for patients with advanced cancer. The incorporation of billed service codes for ACP allows for new inquiries on the association between systematic ACP and improved EOL outcomes.

Objective: Using the IBM MarketScan® Database, we conducted a retrospective medical claims analysis for patients with an advanced cancer diagnosis and referral to hospice between January 2016 and December 2017. We evaluated the association between billed ACP services and EOL hospital admissions in the final 30 days of life.

Design: This is a cross-sectional retrospective cohort study.

Participants: A total of 3,705 patients met the study criteria.

Main measures: ACP was measured via the presence of a billed ACP encounter (codes 99497 and 99498) prior to the last 30 days of life; hospital admissions included a dichotomous indicator for inpatient admission in the final 30 days of life.

Key results: Controlling for key covariates, patients who received billed ACP were less likely to experience inpatient hospital admissions in the final 30 days of life compared to those not receiving billed ACP (OR: 0.34; p < 0.001).

Conclusion: The receipt of a billed ACP encounter is associated with reduced EOL hospital admissions in a population of patients with advanced cancer on hospice care. Strategies for consistent, anticipatory delivery of billable ACP services prior to hospice referral may prevent potentially undesired late-life hospital admissions.

Keywords: end of life; evidence-based practice; reimbursement.

MeSH terms

  • Advance Care Planning*
  • Cross-Sectional Studies
  • Death
  • Hospice Care*
  • Hospices*
  • Humans
  • Neoplasms* / therapy
  • Retrospective Studies
  • Terminal Care*